November 26, 2024 — For the second time this year, we have a meta-analysis of RCTs with GLP-1 medicines that affirms cardiorenal benefits in outcome studies. This latest study appears in Lancet Diabetes and Endocrinology. Lead author Sunil Badve described the importance of his analysis: “This is the first study to show a clear benefit of GLP-1 receptor agonists […]
August 13, 2024 — For the second time in the past few months, a signal from the surveillance of GLP-1 agonists is surfacing to suggest that these drugs may offer a risk reduction strategy for cancer. Earlier, the signal came from a study of persons receiving treatment for diabetes. The present study, presented at the recent annual meeting for […]
May 2, 2023 — Yet again we are reminded that bariatric surgery has quite an impressive record for improving the health of people with obesity. In a retrospective cohort study of 55,789 patients receiving bariatric surgery, risk of obesity-related cancer came down by half. Researchers matched the non-surgical control group using propensity scores for demographics, comorbidity, hormone therapy, and […]
